Biotechnology firm GRI Bio, Inc., has seen encouraging interim results from its ongoing Phase 2a clinical trial evaluating GRI-0621 for the treatment of idiopathic pulmonary fibrosis.

The study’s 6-week biomarker analysis, led by Vitale Miceli of Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione (ISMETT) in Palermo, Italy, theorizes that GRI-0621 can positively influence key processes involved in lung fibrosis, offering a potential new therapeutic avenue for patients.

The findings were published in Nature on July 25. The early data was based on 24 participants and revealed favorable changes in biomarkers associated with fibrogenesis and fibrolysis, the formation and breakdown of fibrous tissue. From the cohort, it found patients treated with GRI-0621 demonstrat

See Full Page